Loading...

OptiNose ($OPTN)

Stock Image

OPTN Overview

OptiNose, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder.The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation.OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania. (From: StockAnalysis.com)

MORE ABOUT OptiNose

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.